Publication: Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States

Delta Hat’s Ash Bullement and Emma Knowles are co-authors on a recent article published in Pharmacoeconomics - Open. The article presents the results of a cost-effectiveness analysis of different recombinant Factor VIII therapies for the treatment of patients with severe haemophilia A without the presence of inhibitors.

You can read the article by following this link: https://pubmed.ncbi.nlm.nih.gov/34268704/